Carregant...
A Bayesian Adaptive Phase I-II Clinical Trial for Evaluating Efficacy and Toxicity with Delayed Outcomes
BACKGROUND: In traditional phase I oncology trials, the safety of a new chemotherapeutic agent is tested in a dose escalation study to identify the maximum tolerated dose, which is defined as the highest dose with acceptable toxicity. An alternate approach is to jointly model toxicity and efficacy a...
Guardat en:
| Autors principals: | , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2013
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3946437/ https://ncbi.nlm.nih.gov/pubmed/24082004 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1740774513500589 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|